Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Pierre-Louis Prost"'
Publikováno v:
American Journal of Hypertension. 7:186-192
The aim of this study was to assess life survival, and arterial and cardiac structural changes following chronic selective beta-blockade in spontaneously hypertensive rats (SHR). Twenty-two SHR aged 3 months and 20 SHR aged 18 months were treated wit
Autor:
Gil-Rch, Yoram Bouhnik, Pierre Clerson, Philippe de Saussure, Pierre-Louis Prost, Nghiep Truong Tan
Publikováno v:
Gastroenterologie clinique et biologique. 31(5)
The strongest environmental factors identified for ulcerative colitis (UC) are cigarette smoking and appendectomy. However, most studies have been performed using case-controls from hospital-based populations. The purpose of this study was to compare
Autor:
Patrick Assyag, Pascal Poncelet, Maxime Guenoun, Alain Cohen Solal, Christine Contre, Pierre Louis Prost, Leurs Irina, Jean Francois Thebaut
Publikováno v:
Archives of Cardiovascular Diseases Supplements. 2:28
RationaleHF treatment is often started during hospitalisation. It appeared interesting to describe the evolution of treatment after hospital discharge.ObjectivesTo describe changes in HF treatment since hospital discharge after stratification on the
Autor:
Patrice Jaillon, Brigitte Lecocq, Pierre Boisson, Pierre-Louis Prost, Odile Fleurot, Vincent Lecocq
Publikováno v:
The American journal of cardiology. 66(5)
Bepridil is a calcium antagonist that prolongs the duration of ventricular repolarization, whereas CERM 4205, another calcium antagonist, seems to be devoid of any effect on QT interval. The aim of this study was to compare the effects of bepridil an
Autor:
Christine Contre, Maxime Guenoun, Jean Francois Thebaut, Pierre Louis Prost, Patrick Assyag, Pascal Poncelet, Leurs Irina, Alain Cohen Solal
Publikováno v:
Archives of Cardiovascular Diseases Supplements. (1):29-30
Rationale Beta blockers are a corner stone treatment of heart failure (HF) in patients with altered systolic function (LVEF 50%) or for patients belonging to the “grey zone” (LVEF 40-50%). Objectives to describe the prescription rate of beta-bloc